cjc 1295 ipamorelin mechanism of action gh igf 1 release CJC-1295 & Blend Dosing: Release, Ratio… CJC-1295 and Ipamorelin Peptide Blend:

Not for human or animal consumption

It is expected that research in animal models using both peptides would indicate greater benefits without significantly raising side effects

The adaptation protocol Start low and increase gradually

Patients who should NOT use it include those with uncontrolled diabetes, active malignancy or personal history of hormone-sensitive cancer, or pituitary disease

Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models

some are investigational drugs not approved by the FDA